Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Primo Biotechnology Co. Ltd. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity is handled by 1 distinct examiner and 1 distinct art unit, indicating a very narrow and specific engagement with the patent office. The limited scope of the data suggests that the company's current legal efforts are directed toward a single specific application. Practitioners should observe that the 1 distinct art unit involved provides a consistent environment for the current prosecution effort.
The busiest examiner for this portfolio is ROGERS, JAMES WILLIAM, who is responsible for 1 busiest examiner pending office action. This matches the total of 1 pending office action for the entire portfolio, signifying that this examiner is the only official currently reviewing the company's work. The use of 1 distinct examiner further centralizes the administrative process. Practitioners should recognize that the 1 busiest examiner pending office action is the sole active item in the portfolio, making the relationship with this specific examiner the primary focus of current prosecution efforts.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, JAMES WILLIAM | 1 | 46.3% | +22.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18054149 | Methods of Noninvasive Detection and Specific Treatment for Cancer Metastasis | ROGERS, JAMES WILLIAM | 43d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18054149 | Methods of Noninvasive Detection and Specific Treatment for Cancer Metastasis | ROGERS, JAMES WILLIAM | 43d overdue |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18054149 | Methods of Noninvasive Detection and Specific Treatment for Cancer Metastasis | ROGERS, JAMES WILLIAM | 1618 | §102§103§112 | Non-Final OA | 43d overdue | Pending | Nov 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrimo Biotechnology Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
James William Rogers has the most, with 1 of Primo Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.